Company Overview
Incannex Healthcare Inc. operates as a clinical-stage biopharmaceutical entity focused on the research and development of psychedelic medicines and therapies designed for patients suffering from chronic diseases within the Australian market. The company functions within the broader Healthcare sector, specifically categorized under the industry of Drug Manufacturers - Specialty & Generic, which implies a focus on developing specialized pharmaceutical products rather than mass-market commodities. As a small-cap entity, Incannex Healthcare Inc. maintains a total market capitalization of $45.27M and employs a workforce of 12 individuals to support its development activities. The current market capitalization of $45.27M, combined with annual revenue data that is not available, indicates that the company operates on a very limited scale typical of early-stage clinical entities that have not yet achieved commercial revenue generation or widespread market penetration.
Financial Health
The company reports net income of $-48,500,000 and EBITDA of $-25,382,000 over the trailing twelve-month period, while revenue figures are currently not available for the trailing twelve months. The significant gap between revenue and net income, alongside the absence of reported revenue, reveals a cost structure where operational expenses and research and development expenditures heavily outweigh current income generation, resulting in a net loss. Free cash flow stands at $-9,415,000, indicating that the company is consuming cash reserves to fund its operations and development pipeline rather than generating surplus cash for distribution or expansion. Gross margin is recorded at 0.0%, operating margin is 0.0%, and profit margin is 0.0%, suggesting that the company has not yet produced commercial sales or has incurred costs that entirely offset its gross revenue, resulting in zero profitability across all margin categories. The company holds cash assets of $68.90M against total debt of $163,000, resulting in a debt-to-equity ratio of 0.22, which demonstrates a highly conservative balance sheet with minimal leverage relative to its cash holdings. A current ratio of 48.27 highlights exceptional short-term liquidity, indicating that the company possesses assets far exceeding its current liabilities and is well-positioned to meet obligations without immediate financial distress. Return on Equity is reported at -130.4% and Return on Assets is -37.0%, metrics that reveal that management has not yet generated positive returns on the capital invested or assets accumulated, a common characteristic for clinical-stage companies still in the development phase.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as N/A due to the absence of positive earnings, while the forward P/E ratio is -1.65, reflecting the expectation of continued negative earnings in the near term. The price-to-book ratio is 0.53, indicating that the market values the company at significantly less than its net asset book value, which often occurs when a company possesses substantial cash reserves relative to its market price. The price-to-sales ratio is infinite (inf) because the company has no reported sales, and the EV/EBITDA stands at 1.18, providing an alternative valuation perspective based on enterprise value relative to earnings before interest, taxes, depreciation, and amortization despite the negative earnings profile. The stock has traded with a 52-week high of $49.80 and a 52-week low of $2.40, illustrating a massive price range where the current market price sits significantly closer to the low end of the historical trading range. The beta value is 2.68, which means the stock exhibits high price volatility that is more than twice as sensitive to movements in the broader market index compared to a stock with a beta of 1.0.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, meaning there is no historical growth data available to compare earnings expansion against revenue expansion at this stage of the company's lifecycle. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, which indicates that the company reinvests all available resources, including its substantial cash balance, back into its research and development efforts rather than distributing income to shareholders. The overall growth and income profile is characterized by a lack of current financial returns and dividend income, relying entirely on the potential future value of its clinical-stage psychedelic medicine pipeline in Australia.